Escherichia coli plays a central role in molecular biology by allowing the cloning, propagation and production of large amounts (up to hundreds of milligrams in fermentors) of highly pure foreign DNA. But cloning in bacterial host largely depends on the presence of convenient restriction endonuclease sites. 1 This dependence leads to limitations on the average size that can easily be manipulated (20 kb) and on the position where the foreign DNA can be inserted. These limitations make the modification of large plasmid-based elements such as BACs and PACs 2,31 very difficult. On the other hand, homologous recombination can be achieved efficiently in the yeast Saccharomyces Cerevisiae. 4 This property has led to the specific introduction of very subtle modifications (base pair change 5 or addition of two base pairs 6 ) in very large DNA molecules (up to 650 kb) cloned in yeast artificial chromosomes (YACs). However, the preparation of good quality DNA from yeast is a time-consuming process and the yields are usually very low, limiting the subsequent functional studies. An extra step is therefore required, where the modified DNA molecule is shuttled to bacteria for large scale production. 7 "ET" cloning.
Recently, Zhang et al. 8 have combined the advantages of both organisms (E. coli and S. Cerevisiae) and described a bacterial system where homologous recombination is as flexible as it is in yeast. The authors demonstrated the possibilities of their system by introducing various modifications in a P1 clone larger than 76 kb. 8 This system relies on the expression of the two proteins Rec E and Rec T in particular bacterial strains and is therefore referred to as "ET" cloning. To be efficient, ET cloning only requires two segments of around 50 nucleotides of homology, flanking the DNA fragment to be cloned. In this issue of Gene Therapy, Narayanan et al. 9 have transferred and adapted the ET cloning strategy to the commonly used, commercially available E. coli strain DH10B and extended the original observations 8 to the modification of a 200 kb BAC carrying the ␤-globin locus. Taken together, these reports demonstrate that ET cloning in bacteria is as efficient and flexible as homologous recombination in yeast, allowing subtle modifications of very large fragments of DNA independently of restriction endonuclease sites while providing the advantages of a classical bacterial host.
Applications to gene therapy. In the case of monogenic diseases, gene therapy strategies usually involve the delivery of a cDNA driven by an heterologous promoter. However, these constructs have the disadvantages of producing non-regulatable levels of expression of the transgene as well as promoting ectopic expression of the cDNA transgene. The availability of a flexible cloning system such as ET recombination offers new opportunities to generate genomic-based DNA constructs containing the coding sequence of the affected gene as well as all the regulatory elements required for tissue-specific "physiological" levels of expression. Starting from a large genomic DNA fragment cloned into a PAC or a BAC, ET homologous recombination provides the technical tool to delete specifically various part of this genomic DNA ( whether located 5' or 3' of the gene, within introns%etc) and to test rapidly the effect of such deletions on parameters such as the level of expression and the cell selectivity of expression of the transgene. Such studies should ultimately lead to the generation of functional maps of a gene and the information could be compacted into a mini-gene with the properties of a much larger locus.
In the case of cancer gene therapy, current strategies include the delivery of "suicide" genes, the delivery of immuno-stimulatory genes or the delivery of genes that will interfere with stromal interactions and inhibit the development of the tumour (i.e. angiostatin). The next step forward for more efficient cancer gene therapy will combine these strategies and will involve the cloning of multiple expression cassettes into single DNA fragments. Once again, ET cloning seems to be the ideal tool to engineer large, multicomponent DNA fragments, particularly at the optimisation stage.
In summary, ET cloning should help to generate better transgenes as well as allow the elaboration of more efficient and sophisticated strategies for gene therapy. These improvements are very likely to increase the size of the DNA fragments which need to be delivered and a possible evolution of the field of gene therapy may depend on the development of delivery vectors with large cloning capacities. In this context, non-viral vectors seem to be ideal (there is no theoretical limitation on the size that they can deliver). However, their efficiency remains to be improved. High capacity, helper-dependent adenoviruses, with a maximal, theoretical capacity of 37 kb 10 of non-viral, exogenous DNA as well as reduced toxicity may be currently the best solution for the delivery of this second generation of transgenes. 
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